Siemens Healthineers – Revenue by Region

Quarterly charts & data from official filings

Timeframe

Revenue by geographic location

Revenue by geographic locationTable view

Earnings release date
Europe, C.I.S., Africa, Middle East (EMEA)
Americas
Asia, Australia
Asia Pacific Japan
China
Total
Earnings release date:31 Jul. 26
Europe, C.I.S., Africa, Middle East (EMEA):
1,950,000,000 €+2.1%
Americas:
2,585,000,000 €+2.0%
Asia, Australia:
–
Asia Pacific Japan:
654,000,000 €-8.3%
China:
576,000,000 €+9.7%
Total:
5,765,000,000 €+1.5%
Earnings release date:07 May. 26
Europe, C.I.S., Africa, Middle East (EMEA):
1,910,000,000 €+5.4%
Americas:
2,534,000,000 €+6.2%
Asia, Australia:
–
Asia Pacific Japan:
713,000,000 €+9.2%
China:
525,000,000 €-4.5%
Total:
5,682,000,000 €+5.2%
Earnings release date:05 Feb. 26
Europe, C.I.S., Africa, Middle East (EMEA):
1,812,000,000 €-14.5%
Americas:
2,387,000,000 €-13.0%
Asia, Australia:
–
Asia Pacific Japan:
653,000,000 €-21.0%
China:
550,000,000 €-12.6%
Total:
5,402,000,000 €-14.5%
Earnings release date:05 Nov. 25
Europe, C.I.S., Africa, Middle East (EMEA):
2,120,000,000 €+16.7%
Americas:
2,745,000,000 €+8.0%
Asia, Australia:
–
Asia Pacific Japan:
827,000,000 €+20.9%
China:
629,000,000 €+1.5%
Total:
6,321,000,000 €+11.6%
Earnings release date:30 Jul. 25
Europe, C.I.S., Africa, Middle East (EMEA):
1,816,000,000 €-0.5%
Americas:
2,542,000,000 €-3.2%
Asia, Australia:
–
Asia Pacific Japan:
684,000,000 €-18.7%
China:
620,000,000 €+0.8%
Total:
5,662,000,000 €-4.2%
Earnings release date:07 May. 25
Europe, C.I.S., Africa, Middle East (EMEA):
1,825,000,000 €+1.8%
Americas:
2,627,000,000 €+10.9%
Asia, Australia:
–
Asia Pacific Japan:
841,000,000 €+19.6%
China:
615,000,000 €-0.5%
Total:
5,908,000,000 €+7.8%
Earnings release date:06 Feb. 25
Europe, C.I.S., Africa, Middle East (EMEA):
1,793,000,000 €-13.3%
Americas:
2,368,000,000 €-12.5%
Asia, Australia:
–
Asia Pacific Japan:
703,000,000 €-18.8%
China:
618,000,000 €-10.0%
Total:
5,482,000,000 €-13.4%
Earnings release date:06 Nov. 24
Europe, C.I.S., Africa, Middle East (EMEA):
2,069,000,000 €+17.0%
Americas:
2,706,000,000 €+12.9%
Asia, Australia:
–
Asia Pacific Japan:
866,000,000 €+33.4%
China:
687,000,000 €+12.4%
Total:
6,328,000,000 €+16.7%
Earnings release date:31 Jul. 24
Europe, C.I.S., Africa, Middle East (EMEA):
1,768,000,000 €-2.3%
Americas:
2,396,000,000 €+6.3%
Asia, Australia:
–
Asia Pacific Japan:
649,000,000 €-16.6%
China:
611,000,000 €+2.7%
Total:
5,424,000,000 €-0.2%
Earnings release date:07 May. 24
Europe, C.I.S., Africa, Middle East (EMEA):
1,810,000,000 €+0.9%
Americas:
2,253,000,000 €+8.7%
Asia, Australia:
–
Asia Pacific Japan:
778,000,000 €+19.5%
China:
595,000,000 €-9.4%
Total:
5,436,000,000 €+5.0%
Earnings release date:01 Feb. 24
Europe, C.I.S., Africa, Middle East (EMEA):
1,794,000,000 €-10.4%
Americas:
2,073,000,000 €-17.2%
Asia, Australia:
–
Asia Pacific Japan:
651,000,000 €-21.7%
China:
657,000,000 €-8.4%
Total:
5,175,000,000 €-14.5%
Earnings release date:08 Nov. 23
Europe, C.I.S., Africa, Middle East (EMEA):
2,002,000,000 €+20.0%
Americas:
2,505,000,000 €+16.0%
Asia, Australia:
–
Asia Pacific Japan:
831,000,000 €+25.7%
China:
717,000,000 €+0.8%
Total:
6,055,000,000 €+16.4%
Earnings release date:02 Aug. 23
Europe, C.I.S., Africa, Middle East (EMEA):
1,669,000,000 €-0.9%
Americas:
2,160,000,000 €+0.9%
Asia, Australia:
–
Asia Pacific Japan:
661,000,000 €-16.9%
China:
711,000,000 €-1.9%
Total:
5,201,000,000 €-2.7%
Earnings release date:10 May. 23
Europe, C.I.S., Africa, Middle East (EMEA):
1,685,000,000 €+3.3%
Americas:
2,140,000,000 €+4.0%
Asia, Australia:
–
Asia Pacific Japan:
795,000,000 €+10.1%
China:
725,000,000 €+8.7%
Total:
5,345,000,000 €+5.3%
Earnings release date:02 Feb. 23
Europe, C.I.S., Africa, Middle East (EMEA):
1,631,000,000 €-10.1%
Americas:
2,057,000,000 €-13.1%
Asia, Australia:
–
Asia Pacific Japan:
722,000,000 €
China:
667,000,000 €
Total:
5,077,000,000 €-15.4%
Earnings release date:09 Nov. 22
Europe, C.I.S., Africa, Middle East (EMEA):
1,814,000,000 €+21.4%
Americas:
2,368,000,000 €-0.3%
Asia, Australia:
1,817,000,000 €+37.9%
Asia Pacific Japan:
–
China:
–
Total:
5,999,000,000 €+15.7%
Earnings release date:03 Aug. 22
Europe, C.I.S., Africa, Middle East (EMEA):
1,494,000,000 €
Americas:
2,374,000,000 €
Asia, Australia:
1,318,000,000 €
Asia Pacific Japan:
–
China:
–
Total:
5,186,000,000 €

Revenue by segment

Revenue by segmentTable view

Earnings release date
Imaging
Diagnostics
Varian
Advanced Therapies
Precision Therapy
Reconciliation to consolidated financial statements
Total
Earnings release date:31 Jul. 26
Imaging:
2,981,000,000 €+1.1%
Diagnostics:
992,000,000 €+0.8%
Varian:
–
Advanced Therapies:
–
Precision Therapy:
1,748,000,000 €+2.8%
Reconciliation to consolidated financial statements:
43,000,000 €-6.5%
Total:
5,764,000,000 €+1.5%
Earnings release date:07 May. 26
Imaging:
2,949,000,000 €+6.5%
Diagnostics:
984,000,000 €+0.0%
Varian:
–
Advanced Therapies:
–
Precision Therapy:
1,701,000,000 €+6.1%
Reconciliation to consolidated financial statements:
46,000,000 €+4.5%
Total:
5,680,000,000 €+5.2%
Earnings release date:05 Feb. 26
Imaging:
2,770,000,000 €-21.1%
Diagnostics:
984,000,000 €-10.4%
Varian:
–
Advanced Therapies:
–
Precision Therapy:
1,603,000,000 €
Reconciliation to consolidated financial statements:
44,000,000 €+33.3%
Total:
5,401,000,000 €-14.6%
Earnings release date:05 Nov. 25
Imaging:
3,512,000,000 €+12.9%
Diagnostics:
1,098,000,000 €+3.7%
Varian:
1,087,000,000 €+11.1%
Advanced Therapies:
591,000,000 €+22.1%
Precision Therapy:
–
Reconciliation to consolidated financial statements:
33,000,000 €+3.1%
Total:
6,321,000,000 €+11.6%
Earnings release date:30 Jul. 25
Imaging:
3,110,000,000 €-1.4%
Diagnostics:
1,059,000,000 €-5.6%
Varian:
978,000,000 €-6.1%
Advanced Therapies:
484,000,000 €-12.3%
Precision Therapy:
–
Reconciliation to consolidated financial statements:
32,000,000 €-22.0%
Total:
5,663,000,000 €-4.2%
Earnings release date:07 May. 25
Imaging:
3,153,000,000 €+8.6%
Diagnostics:
1,122,000,000 €+5.1%
Varian:
1,041,000,000 €+7.0%
Advanced Therapies:
552,000,000 €+10.8%
Precision Therapy:
–
Reconciliation to consolidated financial statements:
41,000,000 €+0.0%
Total:
5,909,000,000 €+7.8%
Earnings release date:06 Feb. 25
Imaging:
2,902,000,000 €-15.3%
Diagnostics:
1,068,000,000 €-6.9%
Varian:
973,000,000 €-12.9%
Advanced Therapies:
498,000,000 €-16.0%
Precision Therapy:
–
Reconciliation to consolidated financial statements:
41,000,000 €-6.8%
Total:
5,482,000,000 €-13.4%
Earnings release date:06 Nov. 24
Imaging:
3,426,000,000 €+19.5%
Diagnostics:
1,147,000,000 €+3.5%
Varian:
1,117,000,000 €+20.5%
Advanced Therapies:
593,000,000 €+23.8%
Precision Therapy:
–
Reconciliation to consolidated financial statements:
44,000,000 €+0.0%
Total:
6,327,000,000 €+16.6%
Earnings release date:31 Jul. 24
Imaging:
2,866,000,000 €+0.7%
Diagnostics:
1,108,000,000 €+0.5%
Varian:
927,000,000 €+1.9%
Advanced Therapies:
479,000,000 €-8.8%
Precision Therapy:
–
Reconciliation to consolidated financial statements:
44,000,000 €-12.0%
Total:
5,424,000,000 €-0.2%
Earnings release date:07 May. 24
Imaging:
2,847,000,000 €+5.9%
Diagnostics:
1,103,000,000 €+4.3%
Varian:
910,000,000 €-0.1%
Advanced Therapies:
525,000,000 €+10.8%
Precision Therapy:
–
Reconciliation to consolidated financial statements:
50,000,000 €+16.3%
Total:
5,435,000,000 €+5.0%
Earnings release date:01 Feb. 24
Imaging:
2,689,000,000 €-16.2%
Diagnostics:
1,058,000,000 €-12.5%
Varian:
911,000,000 €-10.4%
Advanced Therapies:
474,000,000 €-16.7%
Precision Therapy:
–
Reconciliation to consolidated financial statements:
43,000,000 €-15.7%
Total:
5,175,000,000 €-14.5%
Earnings release date:08 Nov. 23
Imaging:
3,210,000,000 €+16.6%
Diagnostics:
1,209,000,000 €+10.8%
Varian:
1,017,000,000 €+21.1%
Advanced Therapies:
569,000,000 €+19.0%
Precision Therapy:
–
Reconciliation to consolidated financial statements:
51,000,000 €+30.8%
Total:
6,056,000,000 €+16.4%
Earnings release date:02 Aug. 23
Imaging:
2,753,000,000 €-1.6%
Diagnostics:
1,091,000,000 €+0.9%
Varian:
840,000,000 €-10.0%
Advanced Therapies:
478,000,000 €-3.4%
Precision Therapy:
–
Reconciliation to consolidated financial statements:
39,000,000 €+5.4%
Total:
5,201,000,000 €-2.7%
Earnings release date:10 May. 23
Imaging:
2,799,000,000 €+6.0%
Diagnostics:
1,081,000,000 €-5.8%
Varian:
933,000,000 €+21.2%
Advanced Therapies:
495,000,000 €+4.7%
Precision Therapy:
–
Reconciliation to consolidated financial statements:
37,000,000 €-21.3%
Total:
5,345,000,000 €+5.3%
Earnings release date:02 Feb. 23
Imaging:
2,641,000,000 €-16.1%
Diagnostics:
1,147,000,000 €-20.5%
Varian:
770,000,000 €-6.1%
Advanced Therapies:
473,000,000 €-17.9%
Precision Therapy:
–
Reconciliation to consolidated financial statements:
47,000,000 €+235.7%
Total:
5,078,000,000 €-15.4%
Earnings release date:09 Nov. 22
Imaging:
3,147,000,000 €+24.7%
Diagnostics:
1,442,000,000 €+2.3%
Varian:
820,000,000 €+2.6%
Advanced Therapies:
576,000,000 €+28.6%
Precision Therapy:
–
Reconciliation to consolidated financial statements:
14,000,000 €+133.3%
Total:
5,999,000,000 €+15.7%
Earnings release date:03 Aug. 22
Imaging:
2,524,000,000 €
Diagnostics:
1,409,000,000 €
Varian:
799,000,000 €
Advanced Therapies:
448,000,000 €
Precision Therapy:
–
Reconciliation to consolidated financial statements:
6,000,000 €
Total:
5,186,000,000 €

Operating expenses

Operating expensesTable view

Earnings release date
Cost of sales
Research and development expenses
Selling and general administrative expenses
Other operating expenses
Total
Earnings release date:31 Jul. 26
Cost of sales:
3,314,000,000 €-6.4%
Research and development expenses:
488,000,000 €+0.4%
Selling and general administrative expenses:
1,008,000,000 €+4.7%
Other operating expenses:
11,000,000 €+37.5%
Total:
4,821,000,000 €-3.5%
Earnings release date:07 May. 26
Cost of sales:
3,539,000,000 €+6.4%
Research and development expenses:
486,000,000 €+2.1%
Selling and general administrative expenses:
963,000,000 €+4.1%
Other operating expenses:
8,000,000 €+33.3%
Total:
4,996,000,000 €+5.6%
Earnings release date:05 Feb. 26
Cost of sales:
3,326,000,000 €-15.8%
Research and development expenses:
476,000,000 €-4.6%
Selling and general administrative expenses:
925,000,000 €-5.1%
Other operating expenses:
6,000,000 €-45.5%
Total:
4,733,000,000 €-12.9%
Earnings release date:05 Nov. 25
Cost of sales:
3,948,000,000 €+13.4%
Research and development expenses:
499,000,000 €+1.2%
Selling and general administrative expenses:
975,000,000 €+3.0%
Other operating expenses:
11,000,000 €+10.0%
Total:
5,433,000,000 €+10.2%
Earnings release date:30 Jul. 25
Cost of sales:
3,481,000,000 €-2.9%
Research and development expenses:
493,000,000 €+1.6%
Selling and general administrative expenses:
947,000,000 €-4.4%
Other operating expenses:
10,000,000 €+25.0%
Total:
4,931,000,000 €-2.7%
Earnings release date:07 May. 25
Cost of sales:
3,586,000,000 €+7.7%
Research and development expenses:
485,000,000 €+0.8%
Selling and general administrative expenses:
991,000,000 €+1.8%
Other operating expenses:
8,000,000 €+60.0%
Total:
5,070,000,000 €+5.9%
Earnings release date:06 Feb. 25
Cost of sales:
3,330,000,000 €-15.1%
Research and development expenses:
481,000,000 €-3.0%
Selling and general administrative expenses:
973,000,000 €+1.1%
Other operating expenses:
5,000,000 €-37.5%
Total:
4,789,000,000 €-11.1%
Earnings release date:06 Nov. 24
Cost of sales:
3,921,000,000 €+17.6%
Research and development expenses:
496,000,000 €+2.5%
Selling and general administrative expenses:
962,000,000 €+4.8%
Other operating expenses:
8,000,000 €-42.9%
Total:
5,387,000,000 €+13.4%
Earnings release date:31 Jul. 24
Cost of sales:
3,333,000,000 €-2.8%
Research and development expenses:
484,000,000 €+2.1%
Selling and general administrative expenses:
918,000,000 €+2.1%
Other operating expenses:
14,000,000 €-71.4%
Total:
4,749,000,000 €-2.1%
Earnings release date:07 May. 24
Cost of sales:
3,429,000,000 €+6.8%
Research and development expenses:
474,000,000 €+2.2%
Selling and general administrative expenses:
899,000,000 €-0.3%
Other operating expenses:
49,000,000 €+512.5%
Total:
4,851,000,000 €+5.8%
Earnings release date:01 Feb. 24
Cost of sales:
3,211,000,000 €-14.7%
Research and development expenses:
464,000,000 €-4.3%
Selling and general administrative expenses:
902,000,000 €-4.2%
Other operating expenses:
8,000,000 €-27.3%
Total:
4,585,000,000 €-11.9%
Earnings release date:08 Nov. 23
Cost of sales:
3,764,000,000 €+15.3%
Research and development expenses:
485,000,000 €+2.3%
Selling and general administrative expenses:
942,000,000 €+6.9%
Other operating expenses:
11,000,000 €-26.7%
Total:
5,202,000,000 €+12.2%
Earnings release date:02 Aug. 23
Cost of sales:
3,265,000,000 €-12.3%
Research and development expenses:
474,000,000 €+1.9%
Selling and general administrative expenses:
881,000,000 €-2.4%
Other operating expenses:
15,000,000 €-78.9%
Total:
4,635,000,000 €-10.2%
Earnings release date:10 May. 23
Cost of sales:
3,723,000,000 €+15.6%
Research and development expenses:
465,000,000 €+5.4%
Selling and general administrative expenses:
903,000,000 €+2.4%
Other operating expenses:
71,000,000 €+195.8%
Total:
5,162,000,000 €+13.0%
Earnings release date:02 Feb. 23
Cost of sales:
3,220,000,000 €-12.5%
Research and development expenses:
441,000,000 €-11.3%
Selling and general administrative expenses:
882,000,000 €-6.1%
Other operating expenses:
24,000,000 €+166.7%
Total:
4,567,000,000 €-10.9%
Earnings release date:09 Nov. 22
Cost of sales:
3,678,000,000 €+10.9%
Research and development expenses:
497,000,000 €+14.0%
Selling and general administrative expenses:
939,000,000 €+11.8%
Other operating expenses:
9,000,000 €+125.0%
Total:
5,123,000,000 €+11.4%
Earnings release date:03 Aug. 22
Cost of sales:
3,317,000,000 €
Research and development expenses:
436,000,000 €
Selling and general administrative expenses:
840,000,000 €
Other operating expenses:
4,000,000 €
Total:
4,597,000,000 €

Profitability

ProfitabilityTable view

Earnings release date
Net income (shareholders)
Free cash flow
Total
Earnings release date:31 Jul. 26
Net income (shareholders):
669,000,000 €+32.2%
Free cash flow:
1,023,000,000 €+162.3%
Total:
1,692,000,000 €+88.8%
Earnings release date:07 May. 26
Net income (shareholders):
506,000,000 €+12.7%
Free cash flow:
390,000,000 €+17.8%
Total:
896,000,000 €+14.9%
Earnings release date:05 Feb. 26
Net income (shareholders):
449,000,000 €-23.6%
Free cash flow:
331,000,000 €-61.6%
Total:
780,000,000 €-46.2%
Earnings release date:05 Nov. 25
Net income (shareholders):
588,000,000 €+6.5%
Free cash flow:
863,000,000 €+2.3%
Total:
1,451,000,000 €+3.9%
Earnings release date:30 Jul. 25
Net income (shareholders):
552,000,000 €+4.2%
Free cash flow:
844,000,000 €+326.3%
Total:
1,396,000,000 €+91.8%
Earnings release date:07 May. 25
Net income (shareholders):
530,000,000 €+11.8%
Free cash flow:
198,000,000 €-75.6%
Total:
728,000,000 €-43.3%
Earnings release date:06 Feb. 25
Net income (shareholders):
474,000,000 €-23.1%
Free cash flow:
810,000,000 €-33.9%
Total:
1,284,000,000 €-30.3%
Earnings release date:06 Nov. 24
Net income (shareholders):
616,000,000 €+31.3%
Free cash flow:
1,226,000,000 €+124.5%
Total:
1,842,000,000 €+81.5%
Earnings release date:31 Jul. 24
Net income (shareholders):
469,000,000 €+10.1%
Free cash flow:
546,000,000 €+355.0%
Total:
1,015,000,000 €+85.9%
Earnings release date:07 May. 24
Net income (shareholders):
426,000,000 €-1.2%
Free cash flow:
120,000,000 €-49.6%
Total:
546,000,000 €-18.4%
Earnings release date:01 Feb. 24
Net income (shareholders):
431,000,000 €-19.7%
Free cash flow:
238,000,000 €-57.3%
Total:
669,000,000 €-38.8%
Earnings release date:08 Nov. 23
Net income (shareholders):
537,000,000 €+20.7%
Free cash flow:
557,000,000 €+95.4%
Total:
1,094,000,000 €+49.9%
Earnings release date:02 Aug. 23
Net income (shareholders):
445,000,000 €+323.8%
Free cash flow:
285,000,000 €-44.8%
Total:
730,000,000 €+17.6%
Earnings release date:10 May. 23
Net income (shareholders):
105,000,000 €-75.1%
Free cash flow:
516,000,000 €+770.1%
Total:
621,000,000 €+80.5%
Earnings release date:02 Feb. 23
Net income (shareholders):
421,000,000 €-33.2%
Free cash flow:
-77,000,000 €-117.0%
Total:
344,000,000 €-68.3%
Earnings release date:09 Nov. 22
Net income (shareholders):
630,000,000 €+73.6%
Free cash flow:
454,000,000 €-5.0%
Total:
1,084,000,000 €+28.9%
Earnings release date:03 Aug. 22
Net income (shareholders):
363,000,000 €
Free cash flow:
478,000,000 €
Total:
841,000,000 €

Profit margin in %

Profit margin in %Table view

Earnings release date
Profit margin (shareholders)
Profit margin (free cash flow)
Earnings release date:31 Jul. 26
Profit margin (shareholders):
11.61 %+2.7 pp
Profit margin (free cash flow):
17.75 %+10.9 pp
Earnings release date:07 May. 26
Profit margin (shareholders):
8.91 %+0.6 pp
Profit margin (free cash flow):
6.87 %+0.7 pp
Earnings release date:05 Feb. 26
Profit margin (shareholders):
8.31 %-1.0 pp
Profit margin (free cash flow):
6.13 %-7.5 pp
Earnings release date:05 Nov. 25
Profit margin (shareholders):
9.3 %-0.4 pp
Profit margin (free cash flow):
13.65 %-1.3 pp
Earnings release date:30 Jul. 25
Profit margin (shareholders):
9.75 %+0.8 pp
Profit margin (free cash flow):
14.9 %+11.6 pp
Earnings release date:07 May. 25
Profit margin (shareholders):
8.97 %+0.3 pp
Profit margin (free cash flow):
3.35 %-11.4 pp
Earnings release date:06 Feb. 25
Profit margin (shareholders):
8.65 %-1.1 pp
Profit margin (free cash flow):
14.78 %-4.6 pp
Earnings release date:06 Nov. 24
Profit margin (shareholders):
9.74 %+1.1 pp
Profit margin (free cash flow):
19.38 %+9.3 pp
Earnings release date:31 Jul. 24
Profit margin (shareholders):
8.65 %+0.8 pp
Profit margin (free cash flow):
10.07 %+7.9 pp
Earnings release date:07 May. 24
Profit margin (shareholders):
7.84 %-0.5 pp
Profit margin (free cash flow):
2.21 %-2.4 pp
Earnings release date:01 Feb. 24
Profit margin (shareholders):
8.33 %-0.5 pp
Profit margin (free cash flow):
4.6 %-4.6 pp
Earnings release date:08 Nov. 23
Profit margin (shareholders):
8.87 %+0.3 pp
Profit margin (free cash flow):
9.2 %+3.7 pp
Earnings release date:02 Aug. 23
Profit margin (shareholders):
8.56 %+6.6 pp
Profit margin (free cash flow):
5.48 %-4.2 pp
Earnings release date:10 May. 23
Profit margin (shareholders):
1.96 %-6.3 pp
Profit margin (free cash flow):
9.65 %+11.2 pp
Earnings release date:02 Feb. 23
Profit margin (shareholders):
8.29 %-2.2 pp
Profit margin (free cash flow):
-1.52 %-9.1 pp
Earnings release date:09 Nov. 22
Profit margin (shareholders):
10.5 %+3.5 pp
Profit margin (free cash flow):
7.57 %-1.6 pp
Earnings release date:03 Aug. 22
Profit margin (shareholders):
7 %
Profit margin (free cash flow):
9.22 %

Capital expenditure

Capital expenditureTable view

Earnings release date
Capital expenditure
Earnings release date:31 Jul. 26
Capital expenditure:
210,000,000 €+15.4%
Earnings release date:07 May. 26
Capital expenditure:
182,000,000 €+13.0%
Earnings release date:05 Feb. 26
Capital expenditure:
161,000,000 €-38.5%
Earnings release date:05 Nov. 25
Capital expenditure:
262,000,000 €+37.2%
Earnings release date:30 Jul. 25
Capital expenditure:
191,000,000 €-2.1%
Earnings release date:07 May. 25
Capital expenditure:
195,000,000 €+14.7%
Earnings release date:06 Feb. 25
Capital expenditure:
170,000,000 €-20.2%
Earnings release date:06 Nov. 24
Capital expenditure:
213,000,000 €+15.1%
Earnings release date:31 Jul. 24
Capital expenditure:
185,000,000 €+11.4%
Earnings release date:07 May. 24
Capital expenditure:
166,000,000 €+25.8%
Earnings release date:01 Feb. 24
Capital expenditure:
132,000,000 €-45.2%
Earnings release date:08 Nov. 23
Capital expenditure:
241,000,000 €+25.5%
Earnings release date:02 Aug. 23
Capital expenditure:
192,000,000 €-6.3%
Earnings release date:10 May. 23
Capital expenditure:
205,000,000 €+2.5%
Earnings release date:02 Feb. 23
Capital expenditure:
200,000,000 €-29.6%
Earnings release date:09 Nov. 22
Capital expenditure:
284,000,000 €+52.7%
Earnings release date:03 Aug. 22
Capital expenditure:
186,000,000 €